Shenzhen releases "Ten Measures for the Cellular Industry" to promote the rapid development of the cellular and genetic industry.

Recently, the Development and Reform Commission of Shenzhen, in conjunction with the Municipal Science and Technology Innovation Bureau, issued the "Work Plan to Promote High-Quality Development in the Field of Cell and Gene Therapy in Shenzhen," introducing ten specific measures. The plan aims to achieve a cell and gene therapy industry scale of 20 billion RMB in the city by 2028, with over 50 IIT projects and the establishment of 2 or more CRO/CDMO service platforms serving over 300 enterprises, focusing on creating a leading hub for cutting-edge technologies, products, innovative enterprises, and talents in the field of cell and gene therapy. Currently, Shenzhen has gathered over 200 cell and gene therapy companies, forming a comprehensive industrial ecosystem covering research and development, clinical trials, preparation, testing, and application. In terms of strengthening investment promotion, the "Ten Measures for Cells" propose to focus on clinical areas such as tumors, genetic diseases, autoimmune diseases, and rare diseases to accelerate the introduction of cell and gene therapy drugs in clinical trial stage and attract innovative enterprises with core technologies. Leveraging the advantages of the Qianhai open policies, efforts will be made to enhance the introduction and services for enterprises with demands for listing in Hong Kong, overseas financing requirements, and foreign investment projects.